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Background. Continued surveillance, and detailed investigation of direct and indirect effects of conjugated vaccines and
risk factors for invasive H.influenzae serotype b (Hib) disease in the vaccine era are important.
Methods. 143 cases with invasive disease between 1991 and 1993 aged 2-16 years were selected retrospectively from
a large incidence trend study. Controls (n = 336) were recruited from local vital registries and matched to cases for age,
gender, and residence. Hib vaccination histories among study subjects and their siblings and other sociodemographic
variables were obtained by questionnaires completed by the parents of these children. Adjusted odds ratio (OR) estimates
were calculated by conditional logistic regression analysis.
Results. Most vaccinated subjects had received the Polysaccharide-Diphtheria Toxoid vaccine and estimated vaccine
efficacy was high (95%; 95% confidence interval [Cl] 60-99%). Also, the results suggested that protection afforded by
vaccination against Hib extended to the family members of vaccinated children. School attendance was found to be
protective against invasive Hib disease (OR : 0.33; C l : 0.14-0.75). Cases more often than controls reported sufferring
from asthma and allergies (OR : 4.8; Cl : 1.2-19.4).
Conclusions. Post-licensure vaccine efficacy is high among children s=2 years of age. The observed association between
asthma and epiglottitis is novel and deserves further investigation.
Keywords: Haemophilus influenzae, vaccine, vaccine efficacy, risk factors, asthma
Haemophilus influenzae type b (Hib) has been a leading
cause of life threatening invasive disease among
children worldwide until vaccines became available in
the mid to late 1980s.1
In the prevaccine era the epidemiology of invasive
Hib disease in Switzerland was comparable to that
of other Western European countries.2 For example,
meningitis occurred at an annual incidence rate of
25 cases per 100 000 children < 5 years of age.2 The
average age at disease was 29 months, higher than,
for instance, in the US. Epiglottitis was as frequent
as meningitis (annual incidence: 25 cases per 100 000
children <5 years old).
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The first conjugate vaccine Polysaccharide-Diphtheria
Toxoid (PRP-D) was licensed in May 1990 and it
was recommended to vaccinate all infants (at age 4, 6
and 15-18 months). As reported from several other
countries, disease rates declined rapidly after the initia-
tion of vaccination.2"6 For example, among children
<5 years of age incidence rates fell by 80% until the
year 1993.2 The average age at disease increased to
35 months.
However, cases of invasive Hib disease continue to
be diagnosed in our country. Continued surveillance,
detailed investigation of direct and indirect vaccine
effects and risk factors for invasive Hib disease in the
vaccine era are therefore important.
METHODS
We conducted a population based case-control study
among Swiss children aged 2-16 years of age for the
time period 1991-1993 to investigate post-licensure
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vaccine efficacy and risk factors for invasive H.influenzae
disease. The study protocol was approved by the ethical
board of the University of Berne and the 26 state physi-
cians of Switzerland. In addition, consent was obtained
from designated people for data protection upon request
by the state physicians.
Cases were selected from a retrospective study2 on
the incidence of invasive H.influenzae disease among
children 0-16 years of age and residing in Switzerland
between 1980 and 1993. Data had been collected from
hospital statistics and by chart review for patients, who
were diagnosed in any of 39 participating Swiss paedi-
atric clinics with culture proven meningitis, epiglottitis,
arthritis, cellulitis, or bacteraemia. In addition, clinic-
ally diagnosed epiglottitis cases were included.
Eligible for the current case-control study were pa-
tients who were hospitalized between 1 January 1991
and 31 December 1993 and had survived their disease.
Cases had to be 3=2 years of age in 1991, 2=3 years old
in 1992 and 3=4 years old in 1993. Age restriction had
the purpose of increasing the probability that a case was
not vaccinated (born before 1990), but had younger
siblings eligible for vaccination. Cases had to be of
Swiss or Italian nationality (residing in Switzerland).
The eligibility criteria were met by 143 cases.
Seventy-nine (55.2%) cases contracted the disease in
1991. The corresponding numbers for 1992 and 1993
were 44 (30.8%) and 20 (14%) cases, respectively. Forty-
four (30.8%) had meningitis, 91 (63.6%) had epiglot-
titis, and 8 (5.9%) arthritis (n = 1), cellulitis (n = 1),
bacteraemia (n = 2), or pneumonia (n = 3). Among
epiglottitis cases the diagnosis was culture confirmed in
67 (73.6%) patients.
Controls were selected from vital statistics registries
and were matched to cases by age (±0.5 years), gender,
and the political community in which the case lived
at disease onset. Five controls per case were recruited
randomly if a community had five or more eligible
children; otherwise, all eligibles were included. Out of
120 vital registries contacted, 109 (91%) participated in
control selection and provided the names and addresses
of 542 controls.
A self-administered questionnaire in German, French
or Italian was sent to case and control families.
Questionnaires were accompanied by a letter asking
for participation. A second and third reminding letter
and questionnaire were sent after 4 and 8 weeks, if no
response was obtained. One hundred and thirty-nine
(97%) of 143 case families and 539 (99%) of 542 con-
trol families for whom a current address was available,
were contacted. Overall, questionnaires were returned
by 121 (87.0%) cases and 399 (74.0%) controls within
12 weeks. Eight (6.7%) cases had one matched control,
20 (19.6%) cases had two controls, 24 (20%) cases had
three controls, 31 (25.8%) cases had four controls, and
19 (15.8%) cases had five controls. Nineteen (15.8%)
cases and 19 (15.8%) controls had no matching control
or case, respectively. Therefore, 102 cases and 336
controls who had at least one matched control or case
remained for further analysis.
The questionnaire asked about a) the family struc-
ture, b) the history of Hib vaccination on all children in
the household as listed in the vaccine booklet, c) day
care, kindergarden or school attendance and the number
of children sharing a bedroom during the year of dis-
ease or reference date, d) chronic disease in any of the
children, e) a history of meningitis or epiglottitis in any
family member, and f) the number of smokers in the
family. Only the question on chronic diseases was open
ended and asked for: 'any chronic disease in a child
living in the household, e.g. cancer or asthma'. Also,
parents were asked for permission to contact their
family physician for further completion of vaccination
histories if necessary. Vaccine history was obtained
from the family physician for five controls, but for none
of four cases for whom data were missing in the
questionnaire.
A reference date was chosen as the day when the case
had been hospitalized with invasive H.influenzae
disease. Cases and controls were considered vaccinated
against Hib if they had received at least one dose of
a conjugated vaccine more than 14 days before the
hospitalization or reference date.
Statistical associations between categories were
evaluated by the %2 t e s t w^ Yates' correction or
Fisher's exact test. Crude and adjusted odd ratios (OR)
were estimated in a conditional logistic regression
model using EGRET.8 Vaccine efficacy was calculated
as (1-OR) x 100%, where OR estimates the relative risk
of disease comparing vaccinated to non-vaccinated
children. The following variables were evaluated as
confounders: family size, the number of siblings, the
number of siblings sharing a bedroom with the case/
control, the number of adult household members, day
care, kindergarden or school attendance, the number
of smokers in the family, and the presence of chronic
diseases.
RESULTS
Data obtained from chart review during the incidence
study of invasive H.influenzae disease in Switzerland2
showed that there was little difference in the clinical
and sociodemographic characteristics of the cases that
were included in the analysis (n = 102) and those that
were not (n = 41) (data not shown). Table 1 presents the
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TABLE 1 Sociodemographic and clinical characteristics of 102
cases and 336 matched controls, Switzerland 1991-1993
TABLE 2 Conditional logistic regression analysis for risk factors
of invasive H.influenzae disease among children 2-16 years of
age, Switzerland, 1991-1993
Cases Controls
Total 102 100 336 100
Age:
2 8 7.8 18 5.4
3-4 47 46.1 156 46.4
3=5 47 46.1 162 48.2
Gender:
Female 43 42.1 146 43.5
Male 59 57.9 190 56.5
Family size:
2 2 1.9 2 0.6
3 17 16.7 31 9.2
2=4 83 81.4 303 90.2
Sharing bedroom:
No 62 60.8 196 58.3
1 sibling 31 30.4 108 32.1
2=2 siblings 7 6.9 29 8.6
Missing 2 1.9 3 1.0
Day care attendance:
No 63 61.8 220 65.4
1-4 hours/week 27 26.5 63 18.8
> 4 hours/week 11 10.7 49 14.6
Missing 1 1.0 4 1.2
Day care group size:
0 63 61.8 220 65.6
<10 25 24.5 67 20.0
2=10 10 9.8 38 11.3
Missing 4 3.9 11 3.3
Kindergarden/school:
No 64 62.8 169 50.3
Yes 38 37.2 167 49.7
Siblings day care attendance:
No 85 83.3 267 79.5
1-4 hours/week 8 7.8 37 11
> 4 hours/week 9 8.8 30 8.9
Missing 0 0 2 0.6
Siblings kindergarden/school:
No 51 50 144 42.9
Yes 51 50 192 57.1
Smokers:
0 60 58.8 207 61.6
1 26 25.5 83 24.7
2=2 14 13.7 43 12.8
Missing 2 2.0 3 0.9
Chronic disease:
No 88 86.3 316 94
Asthma 7 6.8 16 4.8
Allergy 5 3.9 4 1.2
Other 2 2.0 0 0
OR a OR"
crude adjusted
9 5 % CI b
Vaccination 0.06
Day care attendance:
(S4C, > 4 hours/week) 0.69
School attendance (noc, yes) 0.27
Adults:
2C 1.0
1 3.15
3=3 0.78
Siblings < 4 years old (0, 1, 2,5=3) 0.94
Siblings day care attendance:
(S4C , > 4 hours/week)
Siblings school attendance:
(noc, yes)
Sharing bedrooms (n)
Smokers (n)
0.95
0.74
0.93
1.05
0.05
0.61
0.33
1.0
3.52
0.83
1.00
1.01
0.55
1.03
1.10
0-0.40
0.24-1.52
0.14-0.75
1.0-15.37
0.30-2.27
0.62-1.64
0.37-2.95
0.32-0.99
0.57-1.89
0.76-1.57
aOdds ratio crude or adjusted for all other variables in the model.
Analysis on 93 of 102 matched sets; 19 patients had missing values.
b95% confidence interval.
c
 Reference group.
distribution of the matching variables and selected
sociodemographic characteristics of cases and controls.
During the 3 years after the introduction of conjugated
vaccine the average age at disease rose among children
older than one'year by 2 months. However, the skewed
age distribution of cases and controls reflects the age
restriction during sampling.
Only one of 102 cases had been vaccinated compared
to 44 (13.1%) control children. Adjusted vaccine effi-
cacy was therefore calculated to be 95% (95% confid-
ence interval [CI] 59.7-99.4; Table 2). The vaccinated
case had received one dose of a PRP-D vaccine at the
age of 19 months; 8 months before contracting purulent
arthritis. All except two of the controls were vaccinated
with one dose of PRP-D vaccine at age 15 months or
older; two controls got two doses of PRP-D vaccine.
For all three study years (1991-1993) diphtheria toxoid
conjugated vaccine PRP-D (ProHibit®) was the most
frequently used vaccine brand for case or control sib-
lings. It had been given to 120 (75.5%) of 159 case
or control families with at least one vaccinated child.
The PRP-meningococcal outer membrane protein com-
plex conjugate (PedvaxHIB®), the diphtheria protein
INVASIVE H.1NFLUEN2AE DISEASE 1283
TABLE 3 The influence of asthma and allergies on the risk of
invasive H.influenzae disease in non-vaccinated children 2-16
years of age, Switzerland, 1991-1993
Cases Controls OR" ORa 95% CIb
N N crude restricted
TABLE 4 The influence of vaccination of siblings on the risk of
invasive H.influenzae disease in non-vaccinated children 2—16
years of age, Switzerland 1991-1993
Cases Controls ORa ORa 95% CIb
N N crude adjusted
Epiglottitis:
Asthma/Allergies
No'
Yes
Meningitis:
Asthma/Allergies
Noc
Yes
56 (37)
9(7)
26 (25)
2(2)
214(186)
10(6)
81 (72)
8(7)
1.0
3.30
1.0
1.15
1.0
4.80
1.0
0.87
1.18-19.44
0.16-4.72
Siblings vaccinated:
0 23 48
1 6 11
2 0 4
0.30 0.16 0.01-1.56
aOdds ratio crude or restricted to non-vaccinated cases and controls
and to culture proven epiglottitis cases. The figures in parentheses
indicate the number of cases and controls after restriction.
b95% confidence interval.
c
 Reference group; cases and controls with a chronic disease other than
asthma or allergies are excluded.
CRM197 conjugate (Hib TITER®) and the tetanus tox-
oid conjugate PRP-T (ActHIB®) had been administered
in 18 (11.3%), 9 (5.7%) and 1 (0.6%) families. Among
control siblings up to 2 years of age at the reference
date 76.3% (58 of 76) had received at least one dose
of a conjugated vaccine. This percentage vaccinated
increased slightly from 71.4% in 1991, to 84.0% and
77.8% in 1992 and 1993, respectively.
Adjusting for vaccination history, day care, kinder-
garden or school attendance, and smoking there was no
increased risk associated with the number of children in
a family (OR : 0.86; 95% CI : 0.61-1.20; test for trend:
P = 0.36), the number of siblings < 4 years of age
(OR: 1.0, 95% CI : 0.62-1.61), or having siblings
4-16 years of age (OR: 1.11, 95% CI : 0.59-2.08).
Also, sharing a bedroom with siblings was not a risk
factor (OR : 1.03; 95% CI : 0.57-1.89). In six case and
six control families the mother was the only adult (Table
1). Having only one adult household member seemed
to be associated with an increased risk of invasive
H.influenzae disease (OR : 3.57, 95% CI : 1.0-12.86)
(Table 2).
Only 11% of cases and 15% of controls attended day
care for more than 4 hours a week (Table 2). Children
with regular day care attendance seemed to have a
relatively lower risk of invasive H.influenzae disease
(adjusted OR: 0.61, 95% CI : 0.24-1.52) (Table 3).
Also, a smaller proportion of cases attended school than
their matched controls (OR : 0.33, 95% CI : 0.14-0.75)
and they less often had siblings who attended school
" Odds ratio restricted to non-vaccinated cases and controls with at least
I sibling <4 years of age and not attending day care >4 hours/week,
kindergarden or school. Adjusted for the number of siblings and day
care, kindergarden or school attendance of siblings.
b95% confidence interval. Test for trend: P - 0.16.
(OR : 0.65, 95% CI : 0.44-0.97) (Table 3). Restricting
the analysis to cases and controls <6 years of age did
not appreciably influence the OR estimate (data not
presented).
The presence of smokers in a family did not increase
the risk of invasive H.influenzae disease in this study
population (OR : 1.05, 95% CI : 0.76-1.57).
Seven cases and 16 controls had a history of asthma
and four cases and four controls had an 'allergy'. Only
three cases and three controls specified their disease as
allergic asthma or allergic rhinitis. The proportion
of case and control families who mentioned a sibling
with a chronic disease were similar, namely 4% and 6%
(Table 1). One case had epilepsy and another case suf-
fered from Crohn's disease. Asthma and allergies taken
together were associated with an increased risk of
culture proven epiglottitis among non-vaccinated cases
and controls (OR : 4.8, C I : 1.2-19.4) (Table 3).
Analysed separately, the OR estimate associated with
asthma was 5.5 (95% CI : 1.0-29.7) and for allergies the
OR was 3.3 (95% CI : 0.2-40.0). However, a history
of asthma and allergies did not increase the risk for
H.influenzae meningitis (Table 3).
In order to evaluate if Hib vaccination of siblings
conferred indirect protection on other family members,
the study population was restricted to 29 cases and
63 controls who were not vaccinated, had at least one
sibling 4 years of age or younger and did not attend
day care (more than 4 hours a week), kindergarden or
school. Fifteen controls (25.6%) had at least one vac-
cinated sibling in contrast to six (20.7%) cases. The
relative risk associated with having vaccinated siblings
was 0.16 (95% CI : 0.01-1.56, test for trend: /> = 0.I2)
(Table 4).
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DISCUSSION
This case-control study evaluated risk factors of
invasive H.influeniae disease among children 2-16
years of age during a 3-year period after the licensure of
conjugate vaccines in Switzerland. Vaccination was
found to be highly protective against invasive Hib dis-
ease in this study population where the PRP-D was the
most frequently administered vaccine brand. This ob-
servation agrees also with the rapid decline of invasive
Hib disease in Switzerland soon after the initiation of
the vaccine programme.2 However, the PRP-D vaccine
has been found to be less immunogenic9 and it may be
less protective.9'10
Some limitations may be considered when interpret-
ing our study results. While the possibility of confound-
ing is present in every non-randomized study of
treatment efficacy, we feel that confounding is unlikely
to have been responsible for the whole of the observed
association. Within the Swiss population there is no
reason to suggest that the decision to give/receive the
vaccine is related to the disease," and in any event the
association with vaccination per se was adjusted for a
variety of characteristics. Also, in Switzerland socio-
economic standard is uniformly high and school attend-
ance is obligatory. The incidence study from which
cases were recruited also included disease caused by
non-serotype b strains. This should not have had an
important influence on the study result, since over 98%
of disease events were due to serotype b strains.
Recently, Barbour et al.n observed a reduced rate of
nasopharyngeal colonization with Hib among older,
non-vaccinated siblings of vaccinated children. Our
study suggests that vaccination of children also confers
indirect protection from invasive H.influenzae disease
to their older siblings.
Day care attendance has been found to increase the
risk of invasive H.influenzae disease.13"17 However, in
our study control children attended day care more often
than cases. In Switzerland, vaccination is not required
for day care or school attendance. The reason for the
observed association may have been that we studied
children over 2 years of age. Three previous invest-
igations had shown that the risk associated with day care
was highest under the age of 2 years and waned there-
after.131516 Redmond and Picchichero13 hypothesized
that longer duration of day care may lead to greater iso-
immunization (i.e. exposure to cross reactive antigens
carried by other bacteria) and protection from disease.
This may also explain why in our study school attend-
ance among the study subjects and their siblings was
found to be protective.
Recently, Jafari el a/.17 reported that having a single
mother was a risk factor for invasive Hib disease and
delay of vaccination in a post-licensure case-control
study among children 2-18 months of age. Our results
suggested a similar association. However, small num-
bers did not allow us to explore this relationship further.
An interesting observation was that a higher pro-
portion of epiglottitis cases reported a history of asthma
or allergies than did control children. We did not have
more detailed information on the nature of reported
allergies or documentation of asthma. Also, we cannot
exclude that case families were more aware of allergies
or asthma and reported them more often. To our know-
ledge no other study has investigated asthma as a risk
factor for invasive H.influenzae disease. In fact most of
the earlier studies on risk factors have been conducted
in the US where epiglottitis is a rare manifestation
of invasive Hib disease which is itself uncommon in
children of the age group addressed in this study. How-
ever, several observations indicate that damage to the
respiratory mucosa e.g. through other infections or
exposure to smoke may increase the risk of invasive
H.influenzae disease.18"21 Similarly, chronic inflamma-
tion of the respiratory mucosa in asthma patients may
help the bacterium to invade its host. H.influenzae is
able to synthesize histamine and it has been suggested
that the increase in bronchial permeability induced
by histamine may be used by the bacterium to acquire
necessary growth factors from the circulation.22"24
Histamine is also present in high concentrations in
respiratory secretions of asthma patients and may
favour colonization or invasion by H.influenzae. In this
study, asthma was only a risk factor for epiglottitis but
not for meningitis. This may be a consequence of the
relatively high average age of the study population or it
may indicate the role of a local event in the respiratory
tract. The rapidly decreasing incidence of invasive Hib
disease in the vaccine period will make it difficult to
study this question further. However, mucosal damage
through viral infections or smoking has also been found
to increase the risk of invasive infection with Neisseria
meningitidis25 and Streptococcus pneumoniae,26 and the
prevalence of asthma is believed to have been increas-
ing in the last decades.2728 Therefore, the role of asthma
for the pathogenesis of invasive H.influenzae disease
and other bacterial infections deserves further study.
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APPENDIX
Members of the Swiss Haemophilus influenzae study
group
K Baerlocher, (St Gallen), J-P Bossi (Martigny), L G
Buetti (Locarno), U Biihlmann and H Bucher (Zurich),
O Carrel (Vevey), D Chessex (Pompaples), J-M Choffat
(Morges), V D'Appuzzo (Mendrisio), H de Crousaz
(Lausanne), G De"leze (Sion), P Diebold (Monthey),
P Dolivo and K Eggenberger (Yverdon), A Fanconi,
U Lips and D Nadal (Zurich), R Favre (La Chaux-
de-Fonds), H Fricker, (Chur), B Friolet (Delemont),
H Gaze (Neuchatel), M Gianinazi (Lugano), H-P Gnehm
(Aarau), E Gugler (Bern), R M Haller (Munsterlingen),
U Hunziker (Winterthur), F Lattion (Payerne),
D Lauffer (Nyon), J Lutschg (Bruderholz), J-R Panchaud
(Clarens), F Renevey and F Besson (Fribourg),
H Roten, (Visp), G Schubiger (Luzern), H Schwester-
mann (Brig), P Sigg (Zurich), S Suter and A Gervaix
(Genf), F Taminelli (Bellinzona), A Tschumi (Schaff-
hausen), R P Zurbriigg and A Blumberg (Biel).
